Radiopharm Theranostics Limited (RADX)
| Market Cap | 50.84M |
| Revenue (ttm) | 10.86M |
| Net Income (ttm) | -31.07M |
| Shares Out | 3.54B |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,042 |
| Open | 4.500 |
| Previous Close | 4.650 |
| Day's Range | 4.350 - 4.626 |
| 52-Week Range | 3.620 - 16.250 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 15.33 (+250.0%) |
| Earnings Date | May 28, 2026 |
About RADX
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung the... [Read more]
Financial Performance
In fiscal year 2025, Radiopharm Theranostics's revenue was 12.51 million, an increase of 538.86% compared to the previous year's 1.96 million. Losses were -38.34 million, -20.04% less than in 2024.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $15.33, which is an increase of 250.00% from the latest price.
News
Radiopharm Theranostics Reports Business Update
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (t...
Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101
(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) ...
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI.
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinica...
Radiopharm Theranostics Transcript: Study result
Interim phase II-B results for RAD101 in brain metastases show 90% of patients achieving the primary endpoint, with PET imaging providing clear diagnostic value over MRI, especially in equivocal cases. The study is nearing completion, with phase III preparations underway and strong commercial interest reported.
Radiopharm Theranostics Transcript: NWR Virtual Healthcare Conference
RAD101 phase II-B interim results showed strong efficacy in brain metastasis, with final data due by mid-year and phase III planning underway. Multiple first-in-class clinical programs are advancing, with key readouts for RAD204 and RAD202 expected by year-end.
Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
RAD 101 is Radiopharm's novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid...
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases
Radiopharm Theranostics Transcript: Emerging Growth Conference 89
Radiopharm Theranostics presented its clinical-stage pipeline, highlighting first-in-class radiopharmaceuticals for brain metastasis and solid tumors, with key milestones and data expected by 2026. Strategic partnerships and a strong supply chain support its differentiated, therapeutics-focused approach.
RAD Increases Ownership in Radiopharm Ventures to 87.5%
SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative on...
Radiopharm Theranostics Transcript: Study Update
Interim Phase IIb results show that PET imaging with RAD-101 effectively distinguishes active brain metastases from treatment effects, correlates with patient prognosis, and addresses a major unmet need in post-radiosurgery management. The study is progressing well, with a Phase III trial planned and strong market potential projected.
Why Is Radiopharm Theranostics Stock Rallying Over 140%?
Radiopharm Theranostics Limited (NASDAQ: RADX) stock is trading higher on Monday, with a session volume of 21.33 million compared to the average volume of 26.81 thousand, as per data from Benzinga Pro...
Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent b...
Radiopharm Theranostics (RADX): Analyst Maintains 'Buy' as Price Target Adjusts | RADX Stock News
Radiopharm Theranostics (RADX): Analyst Maintains 'Buy' as Price Target Adjusts | RADX Stock News
Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference 2025
The company is advancing a differentiated radiopharmaceutical pipeline, with five key molecules in clinical or near-clinical stages and strong strategic partnerships. Promising early data and a recent capital raise support a cash runway into Q1 2027, with major clinical readouts expected in 2026.
Lantheus (LNTH) Commits to Significant Investment in Radiopharm Theranostics
Lantheus (LNTH) Commits to Significant Investment in Radiopharm Theranostics
Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
SYDNEY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX:RAD; Nasdaq:RADX), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeu...
Regal-backed biotech Radiopharm Theranostics launches $35m placement
The $88 million market cap company had its stockbroker Bell Potter canvassing investor interest at 3¢ per share, an 18.9 per cent discount to the last close.
Radiopharm Theranostics Transcript: KOL Event
The event highlighted the urgent need for better imaging in brain metastases, presenting RAD-101 as a promising, first-in-class PET agent with strong early clinical data and no direct competitors. The ongoing phase 2B study is progressing well, with phase 3 and potential partnerships planned to accelerate market entry.
Radiopharm Theranostics Transcript: KOL Event
KLK3-targeted radiotheranostics offer a highly specific and promising new approach for prostate cancer, addressing limitations of current PSMA therapies. Preclinical and early clinical data show strong efficacy and safety, with first-in-human trials in Australia planned soon.
Radiopharm Theranostics Transcript: KOL Event
Experts highlighted the urgent need for new prostate cancer therapies and introduced B7-H3 as a promising target, with BetaBart engineered for high selectivity and rapid clearance. Preclinical data show strong efficacy and immune memory, and a phase I trial is set to begin following IND clearance.
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radioph...
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025 wit...
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
GARCHING / MUNICH, Germany and SYDNEY, May 19, 2025 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; N...